JY
ESPR

Jeff Yass’s Esperion Therapeutics ESPR Stock Holding History

Jeff Yass’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Sell
657,441
-193,064
-23% -$540K ﹤0.01% 6400
2026
Q1 		$2.33M Sell
850,505
-85,414
-9% -$270K ﹤0.01% 5814
2025
Q4 		$3.46M Sell
935,919
-18,530
-2% -$59.9K ﹤0.01% 4625
2025
Q3 		$2.53M Buy
954,449
+117,988
+14% +$228K ﹤0.01% 5298
2025
Q2 		$823K Buy
836,461
+73,828
+10% +$73.9K ﹤0.01% 7944
2025
Q1 		$1.1M Buy
762,633
+34,401
+5% +$63.4K ﹤0.01% 7009
2024
Q4 		$1.6M Sell
728,232
-27,795
-4% -$64.8K ﹤0.01% 5796
2024
Q3 		$1.25M Buy
756,027
+237,069
+46% +$479K ﹤0.01% 6308
2024
Q2 		$1.15M Sell
518,958
-1,526,811
-75% -$3.59M ﹤0.01% 6254
2024
Q1 		$5.48M Buy
2,045,769
+655,495
+47% +$1.59M ﹤0.01% 3494
2023
Q4 		$4.16M Buy
1,390,274
+792,434
+133% +$1.03M ﹤0.01% 4032
2023
Q3 		$586K Sell
597,840
-45,232
-7% -$65.4K ﹤0.01% 7860
2023
Q2 		$894K Buy
643,072
+335,061
+109% +$468K ﹤0.01% 6959
2023
Q1 		$490K Buy
308,011
+150,776
+96% +$778K ﹤0.01% 8618
2022
Q4 		$980K Buy
157,235
+132,384
+533% +$947K ﹤0.01% 6231
2022
Q3 		$167K Buy
+24,851
New +$171K ﹤0.01% 11096
2022
Q2 		– Sell
-97,136
Closed -$551K – 13151
2022
Q1 		$451K Buy
+97,136
New +$417K ﹤0.01% 9237
2021
Q4 		– Sell
-41,597
Closed -$333K – 13296
2021
Q3 		$501K Sell
41,597
-158,249
-79% -$2.3M ﹤0.01% 9395
2021
Q2 		$4.23M Buy
199,846
+22,530
+13% +$543K ﹤0.01% 4340
2021
Q1 		$4.97M Buy
177,316
+129,040
+267% +$3.81M ﹤0.01% 3927
2020
Q4 		$1.25M Buy
48,276
+30,191
+167% +$904K ﹤0.01% 6158
2020
Q3 		$672K Sell
18,085
-118,154
-87% -$4.68M ﹤0.01% 7046
2020
Q2 		$6.99M Sell
136,239
-52,690
-28% -$2.2M ﹤0.01% 2575
2020
Q1 		$5.96M Buy
188,929
+64,091
+51% +$3.38M ﹤0.01% 2350
2019
Q4 		$7.44M Buy
124,838
+27,119
+28% +$1.22M ﹤0.01% 2447
2019
Q3 		$3.58M Sell
97,719
-42,265
-30% -$1.67M ﹤0.01% 3208
2019
Q2 		$6.51M Buy
139,984
+30,940
+28% +$1.45M ﹤0.01% 2376
2019
Q1 		$4.38M Buy
+109,044
New +$4.89M ﹤0.01% 2614
2018
Q3 		– Sell
-198,000
Closed -$9.09M – 9472
2018
Q2 		$7.76M Buy
+198,000
New +$10M ﹤0.01% 2200
2018
Q1 		– Sell
-115,879
Closed -$8.51M – 9502
2017
Q4 		$7.63M Buy
+115,879
New +$6.24M ﹤0.01% 2077
2017
Q1 		– Sell
-49,983
Closed -$1.14M – 9166
2016
Q4 		$626K Sell
49,983
-51,085
-51% -$608K ﹤0.01% 6519
2016
Q3 		$1.4M Buy
101,068
+44,424
+78% +$503K ﹤0.01% 4171
2016
Q2 		$560K Sell
56,644
-57,910
-51% -$960K ﹤0.01% 5932
2016
Q1 		$1.94M Sell
114,554
-10,058
-8% -$162K ﹤0.01% 3833
2015
Q4 		$2.77M Sell
124,612
-223,488
-64% -$5.64M ﹤0.01% 3436
2015
Q3 		$8.21M Buy
348,100
+92,718
+36% +$5.82M ﹤0.01% 2057
2015
Q2 		$20.9M Buy
255,382
+82,046
+47% +$8.03M 0.01% 1266
2015
Q1 		$16.1M Buy
173,336
+166,887
+2,588% +$10.8M 0.01% 1420
2014
Q4 		$261K Buy
+6,449
New +$197K ﹤0.01% 8368

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Jeff Yass's ESPR Position: Q2 2026 in Review

Jeff Yass reduced its Esperion Therapeutics (ESPR) stake by 23% in Q2 2026, selling an estimated $540K and leaving 657,441 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #6400.

Jeff Yass first reported a position in ESPR in Q4 2014 and has held it in 39 quarters since. The position peaked at $20.9M in Q2 2015. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Jeff Yass held 657,441 shares of Esperion Therapeutics worth $2.08M as of Q2 2026.
  • Jeff Yass sold 193,064 Esperion Therapeutics shares in Q2 2026, an estimated $540K.
  • Esperion Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6400 holding.
  • Jeff Yass first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 39 quarters since.
  • Jeff Yass's Esperion Therapeutics position peaked at $20.9M in Q2 2015.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.